Efficacy and Safety of a Novel Pegylated Interferon Alpha-2a in Egyptian Patients with Genotype 4 Chronic Hepatitis C
BACKGROUND: Hepatitis C virus (HCV) genotype 4 is a common infection in Egypt and is the leading cause of liver disease.
Saved in:
Main Authors: | Alaa Awad Taha, Ahmad El-Ray, Maged El-Ghannam, Bahaa Mounir |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2010/717845 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C
by: Yvette Leung, et al.
Published: (2006-01-01) -
Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01) -
Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy
by: Curtis Cooper, et al.
Published: (2014-01-01) -
Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-03-01) -
Hepatitis C Virus Clearance after Discontinuation of Pegylated Interferon Alpha-2a Monotherapy in a Child
by: Takeshi Endo, et al.
Published: (2012-01-01)